**Guideline Adherence in Dyspepsia Investigation and Treatment**

Katelyn Dugan, MS-3, Elizabeth Ablah, Ph.D., MPH1, Hayrettin Okut, Ph.D.1,2, Sachin Srivinvasan, M.D.3, William Salyers, Jr., M.D., MPH3

1University of Kansas School of Medicine-Wichita, Wichita, KS
2Department of Population Health
3Office of Research
4Department of Internal Medicine

Received July 1, 2020; Accepted for publication Aug. 20, 2020. Published online Dec. 11, 2020

https://doi.org/10.17161/kjm.vol13.13838

**ABSTRACT**

**Introduction.** The impact of dyspepsia guidelines on clinical practice may be poor. Provider adherence with dyspepsia guidelines was examined to determine their impact on clinical practice.

**Methods.** Provider adherence with the 2005 American College of Gastroenterology Guidelines for the Management of Dyspepsia and the 2017 American College of Gastroenterology and Canadian Association of Gastroenterology joint Dyspepsia Management Guidelines was assessed on a national level using data from the National Ambulatory Medical Care Survey (NAMCS). Patient visit data, including reason for visit of dyspepsia, diagnosis of dyspepsia, or diagnosis of *H. pylori* infection from NAMCS years 2012 through 2015, were used. Provider adherence with dyspepsia management guidelines was determined based upon provision of at least one recommended test or treatment for dyspepsia.

**Results.** Providers appeared to adhere to the 2005 ACG guidelines for 49.7% of patient visits. Providers appeared to adhere to the 2017 ACG/CAG guidelines for 51.0% of patient visits.

**Conclusion.** Provider adherence with the 2005 ACG and the 2017 ACG/CAG Dyspepsia Management Guidelines was determined to be low in this study, highlighting the need to increase evidence-based medical treatment and efficient resource use for dyspepsia.

**Kans J Med 2020;13:306-310**

**INTRODUCTION**

Dyspepsia has been described as epigastric pain persisting for one month or more, which may be associated with a range of other clinical gastrointestinal symptoms, including heartburn or epigastric fullness. The prevalence of uninvestigated dyspepsia in North America is approximately 22%, with a suggested incidence of 1.3% annually and peak incidence in the seventh decade of life. Dyspepsia patients can be categorized as (1) uninvestigated if they have not undergone investigation in an attempt to discover underlying disease, (2) investigated, which exposed a cause for their symptoms, or (3) investigated, but no cause was discovered, termed functional dyspepsia, a diagnosis of exclusion. Investigation by endoscopy revealed clinically significant findings in 10.2% of patients, with one study suggesting nonerosive gastritis and another suggesting reflux esophagitis most commonly, were identified. Other underlying causes of dyspepsia included infection of *Helicobacter pylori* (*H. pylori*), gastric or duodenal ulcers, and gastrointestinal malignancy, although functional dyspepsia is the most common cause.

Different tests and procedures may be done to investigate dyspepsia symptoms, some of which are not recommended routinely and may increase healthcare costs for dyspepsia management. Among patients diagnosed with functional dyspepsia, the cost of testing received was estimated to be $582 per patient. These patients underwent blood work (75%), abdominal ultrasound (59%), abdominal x-ray (47%), or abdominal and/or pelvis computed tomography (CT; 40%). None of these tests are recommended routinely for evaluation of dyspepsia by either the 2005 American College of Gastroenterology clinical guidelines or the 2017 American College of Gastroenterology and Canadian Association of Gastroenterology joint guidelines.

The impact of dyspepsia guidelines on clinical practice may be poor. A vignette survey suggested 57% of primary care providers and 74% of gastroenterologists adhered to the 2005 ACG guidelines and other consensus recommendations for dyspepsia investigation and management.

Endoscopy may be overutilized to investigate dyspepsia. One study suggested 37.8% of esophagogastroduodenoscopies (EGD) done for gastrointestinal indications, including dyspepsia, were not indicated by guidelines. A study of dyspepsia patients younger than 55 years without alarm symptoms suggested 58% (rather than 100%) had received both *H. pylori* testing and proton pump inhibitors (PPI) therapy, as the guidelines recommended, before receiving an EGD. However, endoscopy may be underutilized in older age groups, as one study reported 81% of dyspepsia patients 50 years or older had not received endoscopy, despite guideline recommendations. Another study reported similar results; only 27% of dyspepsia patients older than 55 years had received an EGD, rather than 100% if the 2005 guidelines had been followed.

The current study examined dyspepsia investigation and treatment practices for 2012 - 2015. Provider practices were determined to be adherent or nonadherent with the 2005 ACG Guidelines for the Management of Dyspepsia. Adherence with the 2017 ACG and CAG guidelines also was assessed to determine if clinical practices in the years preceding the release of these guidelines had shifted toward utilizing therapies included in the 2017 guidelines, as new knowledge on effective management was identified, but before updated guidelines were released.

**METHODS**

**Participants.** Data were analyzed from the National Ambulatory Medical Care Survey (NAMCS) for 2012 - 2015. Data collected about community health centers were not included. Patient data meeting the following criteria were included: reason(s) for visit including dyspepsia, diagnosis of dyspepsia, or diagnosis of *Helicobacter pylori* infection. Data were excluded if patients were younger than 18 years, or if the patient had a diagnosis of gastroesophageal reflux disease (GERD).

**Instrument.** Non-federally employed, practicing physicians (excluding pathologists, radiologists, and anesthesiologists) working
in ambulatory care settings in the U.S. were eligible to participate in NAMCS. Physician interviews were used to collect physician and healthcare practice data (e.g., specialty, location). Physicians were surveyed for a sample of patient visits during a random one-week period annually. Data recorded about patient visits included demographic information, patient comorbidities, reason(s) for visit, diagnoses related to the visit, services ordered or provided, medications (including prescription and over-the-counter drugs) ordered or provided, and if these medications were new or continued. Drug information, including drug therapeutic classes, for medications ordered or provided during the patient visit, was coded by NAMCS using Lexicon Plus®, a Cerner Multum™, Inc. database.

The variables used from the NAMCS database files for the current study included patient age, body mass index (BMI), sex, unimputed race, unimputed ethnicity, tobacco use, depression comorbidity, reason for visit, diagnoses related to visit, services ordered or provided, and therapeutic class codes for medications ordered or provided. Up to five reasons for five diagnoses could be listed per patient record. For services not specifically listed as a checkbox item on the patient record interview form, up to nine write-in procedure codes could be documented. Up to 10 medications could be listed for years 2012 and 2013, and up to 30 medications could be listed for years 2014 and 2015. For each medication, up to four categories, with three levels per category, could be used to list the drug’s therapeutic class codes from the Lexicon Plus® database.

Data about the physician, including specialty and region of practice within the U.S., were used. Physician specialty was stratified into 14 groups, including general/family practice, internal medicine, and general surgery. Physician specialty was stratified separately into three groups: primary care, surgical care, or medical care specialties. Regions of practice included the northeast, midwest, southwest, and west regions of the U.S.

Procedures. This study was considered “not human subjects” by the University of Kansas School of Medicine-Wichita’s Human Subjects Committee. To assess the frequency of medications ordered or prescribed, drug therapeutic class codes were used. Drug therapeutic classes of interest included antacids, PPIs, H2 antagonists, H. pylori eradication agents, gastrointestinal stimulants, and tricyclic antidepressants (TCA).

The frequency of a diagnosis of H. pylori infection (ICD-9-CM code 041.86) along with one or more write-in procedure codes encompassing noninvasive H. pylori testing recommended by the 2007 ACG H. pylori management guidelines was used to determine the frequency H. pylori tests were ordered or provided (Table 1).

Table 1. Patient characteristics.

| Code | Description |
|------|-------------|
| 89.39 | Other nonoperative measurements and examinations (including 14 C-Urea breath test) |
| 90.59 | Other microscopic examination of blood |
| 90.99 | Other microscopic examination of specimen from lower gastrointestinal tract and of stool |
| 91.39 | Other microscopic examination of specimen from bladder, urethra, prostate, seminal vesicle, perivesical tissue, and of urine and semen |

To assess the frequency of EGD or other upper gastrointestinal endoscopy ordered or provided during a patient visit, data from the checkbox item “upper gastrointestinal endoscopy/EGD” for years 2014 and 2015 were combined with write-in upper endoscopy ICD-9-CM procedure codes for years 2012 through 2015 (Table 2). The combined frequency of the EGD checkbox item and the upper endoscopy procedure codes was used to assess the number of upper endoscopies ordered or performed.

Table 2. Write-in upper endoscopy ICD-9-CM procedure codes.

| Code | Description |
|------|-------------|
| 42.23 | Other esophagoscopy (excludes that with biopsy) |
| 42.24 | Closed [endoscopic] biopsy of esophagus |
| 44.13 | Other gastroscopy (excludes that with biopsy) |
| 44.14 | Closed [endoscopic] biopsy of stomach |
| 45.13 | Other endoscopy of small intestine (includes EGD) |
| 45.16 | EGD with closed biopsy |

To assess provider adherence with the 2005 ACG guidelines, the provision of at least one component of the 2005 guidelines constituted adherence. Specifically, the provision of any upper endoscopy, EGD, acid suppression medication (PPIs), H. pylori eradication agents, or noninvasive H. pylori testing was assessed per patient to determine provider guideline adherence (Figure 1). To assess provider adherence with the 2017 ACG/CAG guidelines, the provision of at least one component of the 2017 guidelines constituted adherence. All components of the 2005 guidelines were included in the 2017 assessment, with the addition of tricyclic antidepressant medications, GI stimulant/prokinetic medications, or psychotherapy (Figure 1). H2 antagonists were included as acceptable acid suppression therapy for adherence with the 2005 and 2017 guidelines in two additional assessments of provider adherence.

Analysis. Data were analyzed using SAS version 9.4 (2019, SAS Int. Inc., Carry, NC). Frequencies, proportion, means, and standard deviations were calculated. Pearson chi-square and likelihood chi-square were used to test the associations between categorical variables. Cochran-Mantel-Haenszel statistics were conducted to determine the relationships between two stratified categorical variables after controlling for at least one variable. These stratified analyses

Figure 1. Criteria for guideline adherence.
provided a way to adjust for the possible confounding effects without being forced to estimate parameters for them. All statistical tests at p ≤ 0.05 were considered significant.

RESULTS

Of the 260,118 patient encounters from 2012 through 2015, 680 records met inclusion/exclusion criteria. Of the 680 records, heartburn and indigestion (dyspepsia; ICD-9-CM code 536.8) was documented as the reason for 58.5% of patient visits (n = 398). The diagnosis of dyspepsia or other specified disorders (ICD-9-CM code 536.8) was listed for 38.2% of patients (n = 260), and the diagnosis of H. pylori infection (ICD-9-CM code 041.86) was listed for 13.1% of patients (n = 89).

Physician participants worked throughout the U.S., with 34.4% practicing primarily in southern states (n = 234), 23.1% in western states (n = 157), 23.1% in the midwest (n = 157), and 19.4% in the northeast (n = 132). Broadly grouped, 49.0% of physicians (n = 333) were in medical care specialties, 42.2% of physicians (n = 287) were in primary care specialties, and 8.8% of physicians (n = 60) were in surgical care specialties. Of the 14 specialty groupings, many physicians (41.0%, n = 194) were categorized into the “other” specialties group, which included gastroenterology. Physicians in the “general or family practice” group made up 20.9% of participants (n = 99), and those in internal medicine made up another 20.9% of participants (n = 99).

As reported by their physicians, most patients (82.3%, n = 415) were White, and 99% of patients (n = 50) were Black or African American. Almost 20% of patients (18.2%, n = 88) were reported to be Hispanic or Latino (Table 3).

Table 3. Patient demographics.

| Ethnicity                | Frequency | Percent |
|--------------------------|-----------|---------|
| Not Hispanic/Latino      | 396       | 81.8%   |
| Hispanic/Latino          | 88        | 18.2%   |
| Missing                  | 196       |         |

Table 4. Management provided.

| Medications (Prescription and Non-Prescription) | Frequency | Percent |
|------------------------------------------------|-----------|---------|
| Proton Pump Inhibitors (PPIs)                  | 281       | 41.3%   |
| H2 Antagonists                                 | 54        | 79.9%   |
| Antacids                                       | 26        | 3.8%    |
| Tricyclic Antidepressants (TCA)                | 12        | 1.8%    |
| GI Stimulants/Prokinetics                      | 11        | 1.6%    |
| H. pylori Testing or Treatment                 |           |         |
| Noninvasive H. pylori Test                     | 20        | 2.9%    |
| H. pylori Eradication Therapy                  | 11        | 1.6%    |

| EGD/Upper Endoscopy                            | 87        | 12.8%   |

When adherence was defined as provision of any component of the 2005 ACG dyspepsia guidelines, providers were considered adherent for 49.7% (n = 338) of patient visits. When adherence was defined as provision of any component of the 2017 ACG/CAG dyspepsia guidelines, providers were considered adherent for 51.0% (n = 347) of patient visits (Table 5). Addition of H2 antagonists for acceptable acid suppression raised adherence to 54.1% of patient visits (n = 368) for the 2005 ACG guidelines and 55.4% of patient visits (n = 377) for the 2017 ACG/CAG guidelines.

Patient mean age was 55 years, and 60.4% of patients (n = 411) were female. Mean patient BMI (n = 521) was 29. Physicians reported that 16.5% of patients (n = 90) were current tobacco users and 10.6% of patients (n = 72) had current depression.

Almost all patients (91.8%, n = 624) had at least one service ordered or provided, including exams, screenings, laboratory tests, imaging, procedures, treatments, health education, or counseling. More than one quarter of physicians (26.3%, n = 179) reported having one or more exams ordered or provided. Almost one in five patients (18.5%, n = 126) had some type of imaging ordered or provided, including an x-ray for 7.2% of patients (n = 49), CT scan for 4.9% of patients (n = 33), or magnetic resonance imaging for 1.3% of patients (n = 9).

One or more write-in procedures were reported for 43.4% of patients (n = 295), for a total of 486 write-in procedures. Procedures included “other microscopic examination of blood” (17.5%, n = 85), upper endoscopy (13.8%, n = 67), “other consultation” (10.1%, n = 49), and general physical examination (3.5%, n = 17).

Of prescription and non-prescription medications reported, antacids were ordered or provided for 3.8% of patients (n = 26). Of the acid suppression medications, PPIs (41.3%, n = 281) were ordered or provided more often than H2 antagonists (7.9%, n = 54). TCAs were ordered or provided for 1.8% of patients (n = 12), and GI stimulants/prokinetics were ordered or provided for 1.6% of patients (n = 11). Psychotherapy was ordered or provided for 0.6% of patients (n = 4).

Noninvasive H. pylori testing was ordered or provided for 2.9% of patients (n = 20). H. pylori eradication therapy was given for 16% of patients (n = 11). Any EGD/upper endoscopy was ordered or provided for 12.8% of patients (n = 87; Table 4).
Table 5. Guideline adherence.

| 2005 ACG Guideline Criteria | Frequency | Percent |
|-----------------------------|-----------|---------|
| Total Adherence from 2012 through 2015 | 338 | 49.7% |
| Adherence in 2012 | 95 | 45.9% |
| Adherence in 2013 | 152 | 53.1% |
| Adherence in 2014 | 67 | 52.8% |
| Adherence in 2015 | 24 | 40.0% |

| 2017 ACG/CAG Guideline Criteria | Frequency | Percent |
|-----------------------------|-----------|---------|
| Total Adherence from 2012 through 2015 | 347 | 51.0% |
| Adherence in 2012 | 95 | 45.9% |
| Adherence in 2013 | 154 | 53.8% |
| Adherence in 2014 | 72 | 56.7% |
| Adherence in 2015 | 26 | 43.3% |

DISCUSSION

The prevalence of dyspepsia in this study was 0.26% (n = 680). A prior study suggested the prevalence of gastritis/dyspepsia to be 1.73% among adults.17 The lower prevalence of dyspepsia within this study may be due to the strict inclusion criteria. It is likely that some patients presenting with dyspepsia were not reported as such by physicians during the patient record interview, and instead another reason for visit or diagnosis was used, such as upper abdominal pain (ICD-9-CM code 545.3 upper abdominal pain, cramps, spasms) or diagnosis of gastric ulcer (ICD-9-CM code 531 Gastric Ulcer). The code for upper abdominal pain was not used for inclusion criteria in this study, as it encompasses more than just epigastric pain and likely would have overestimated the prevalence of dyspeptic patients within the study sample. Likewise, more specific diagnoses, such as gastric ulcers or gastrointestinal malignancy, were not used for inclusion criteria in this study, as they are considered underlying causes of dyspepsia identified on EGD which may require separate therapy.18,19

Diagnosis of H. pylori infection was used for inclusion criteria in this study, as the 2007 ACG Guideline on the Management of Helicobacter pylori Infection recommended diagnosis and treatment for select patients with uninvestigated dyspepsia.16 Although diagnosis of H. pylori is indicated for reasons other than dyspepsia (e.g., peptic ulcer disease, gastric mucosa associated lymphoid tissue or MALT lymphoma), the diagnosis of H. pylori was used to identify a small proportion (13.1%) of the study sample and is unlikely to have a large impact on the results.16 The diagnosis of GERD was used for exclusion, as GERD is considered a different diagnosis for patients presenting mainly with heartburn or acid regurgitation, rather than dominant epigastric discomfort or pain as in dyspepsia.7

The current study suggested dyspepsia to be more common among women. Uninvestigated dyspepsia may be more common among women, with a suggested global prevalence of 25.3% in women compared to 21.9% among men.17 Patient mean age in this study was 55 years, which is slightly older than the mean ages of 47 years and 50 years of two other studies of patients with dyspepsia.8,20

In the current study, 18.5% of patients (n = 126) were ordered or provided an imaging service. A study of patients with persistent dyspepsia suggested that 87.1% of patients had received abdominal imaging, and the most frequent modalities were CT and ultrasound.21 The lower frequency of imaging use in the current study could indicate a decreasing trend as study data were obtained from more recent years, although history of prior or later imaging services provided to patients in this study was not obtainable.

The current study suggested that PPIs were prescribed more often than H2 antagonists. Physician concern about adverse effects of PPI therapy have been suggested, with 52% of internal medicine physicians self-reporting they sometimes or often changed a patient's prescription from PPI therapy to H2 antagonists.22 A prior study suggested H2 antagonists were prescribed more frequently than PPIs in patients with uninvestigated dyspepsia (88.1% versus 47.4%, respectively).23 However, the current study’s findings were consistent with guideline recommendations, and this increased usage of PPIs over H2 antagonists for acid suppression therapy may indicate guideline adherence in this area.19

Half of patients with dyspepsia in this study received at least one treatment, diagnostic test, or exam recommended by either the 2005 ACG or 2017 ACG/CAG guidelines. This percentage of patients receiving care specified within dyspepsia management guidelines was suboptimal and indicated low physician adherence to dyspepsia management guidelines. Furthermore, there was minimal difference between the percent of visits adherent to the 2005 compared to the 2017 guidelines, indicating the additional therapies considered adherent by the 2017 guidelines were not utilized frequently in the years preceding the release of the 2017 guidelines. This limited difference in adherence also clarified that most visits considered non-adherent with the 2005 guidelines were not provided the more novel therapies considered to be adherent by the 2017 guidelines.

Physicians may be non-adherent due to lack of knowledge of guidelines. A review of guideline adherence barriers suggested physicians were more likely to be unfamiliar with guideline content than unaware of their existence.23 Therefore, dissemination of the 2017 ACG/CAG guidelines with its management algorithm to physicians working in ambulatory care settings may improve knowledge and adherence to dyspepsia management guidelines. However, this strategy alone may not be sufficient to raise adherence levels, as passive dissemination of guidelines has been suggested to be ineffective for guideline implementation.24 Further interventions, including workshops, handouts, and reminders, may be beneficial as they have been suggested to lower drug costs of dyspepsia without increasing endoscopy use.25

Increased monitoring of guideline adherence in clinical practices may be beneficial. Notifying providers when their endoscopy referral for dyspepsia management was not adherent with guidelines was suggested to increase adherence rates from 55% to 75%.26 Less targeted approaches to increase physician acceptance and adherence to all clinical guidelines may be useful, as one study suggested clinical practice guidelines only have a large or very large effect on how less than 25% of physicians practice medicine.27 Both targeted and general approaches
to increase guideline adherence may be necessary to ensure evidence-based medicine is practiced.

There were several limitations of this study. NAMCS is a voluntary survey of physicians. As a result, data may be influenced by response and/or recall bias. There was also variability in the number of records meeting inclusion/exclusion criteria per year. The highest number of patient records meeting criteria for this study was 286 records in 2013 and the lowest number was 60 in 2015. The lack of consistency in the total number of patient records available per year from the NAMCS database may have led to increased variability in the data. However, the percentage of records determined to be adherent to guidelines in this study remained low in each year, ranging from 40.0% to 53.1% for the 2005 guidelines and from 43.3% to 56.7% for the 2017 guidelines.

The lack of available CPT codes, the breadth of the ICD-9-CM codes, and the variability in the checkbox items included in the survey from year to year made capturing accurate and consistent data difficult. For example, upper gastrointestinal endoscopy/EGD was included as a checkbox item for examinations/screenings ordered or provided for survey years 2014 and 2015, but not for years 2012 or 2013. Furthermore, appropriateness of the use of treatments or tests for each patient based upon specific indications (such as presence of alarm features, risk of malignancy, or previous treatment or test results) could not be assessed in this cross-sectional study. Additionally, some patients may have not desired or had counter-indications to receiving the guideline recommended test or treatment, making non-adherence acceptable in these specific situations. Therefore, adherence may have been over or underestimated, as the specific order and situational appropriateness of guideline provision could not be assessed.

Despite the challenges of using NAMCS data, the survey captured national, systematic data on ambulatory care practices within the U.S. It is a valuable source of information about clinical practices of U.S. physicians.

CONCLUSIONS

Provider adherence with both the 2005 ACG and the 2017 ACG/CAG dyspepsia management guidelines was determined to be low in this study, with 50% of patients receiving a recommended test or treatment. Physician adherence must increase to evidence-based management of patients with dyspepsia and utilize healthcare resources appropriately and efficiently.

REFERENCES

1. Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017;112(9):1484-1498. PMID: 28762578.
2. Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: A meta-analysis. Gut 2015;64(7):1049-1057. PMID: 25147201.
3. Mapel D, Roberts M, Overhiser A, Mason A. The epidemiology, diagnosis, and cost of dyspepsia and Helicobacter pylori gastritis. A case-control analysis in the Southwestern United States. Helicobacter 2013;18(1):54-65. PMID: 23067108.

Keywords: dyspepsia, gastroenterology, guideline adherence, patient care management, practice guidelines as topic